The HDAC inhibitor “romidepsin” was used in a clinical phase II trial for HNSCC patients, and it was reported that the single agent romidepsin has limited activity for the treatment of HNSCC but can effectively achieve tumor-associated HDAC inhibition [70]. This evidence concerns the gene HDAC9 and head and neck squamous cell carcinoma.